Clinical trial
Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD)
NCT00156962 · Amgen, Industry · Terminated
Key facts
| NCT number | NCT00156962 |
|---|---|
| Title | Epoetin Alfa (EPO) in Subjects With Chronic Kidney Disease (CKD) |
| Official title | A Randomized, Open-Label Study to Assess the Safety of Epoetin Alfa Manufactured by Deep Tank Technology and Epoetin Alfa Manufactured by Roller Bottle Technology in Subjects With Chronic Kidney Disease Not on Dialysis |
| Lead sponsor | Amgen, Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Chronic Kidney Disease |
| Intervention type | Drug |
| Interventions | Epoetin alfa DT, Epoetin alfa RB |
| Enrollment | 850 |
| Start date | Apr 1, 2005 |
| Primary completion | Mar 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Sep 12, 2005 |
| Last update posted | Jul 21, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: